ATG Dosing for GVHD Prevention
Phase II Clinical Trial of 2 Step ATG Combined With Tacrolimus and Mini Methotrexate for Prevention of Acute GVHD Post Reduced Intensity Allogeneic Stem Cell Transplant
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 2
- Enrollment
- 56 patients (estimated)
- Sponsors
- University of Alabama at Birmingham
- Trial Type
- Treatment
- Last Update
- 31 minutes ago
- SparkCures ID
- 1835
- NCT Identifier
- NCT06265584
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.